<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654769</url>
  </required_header>
  <id_info>
    <org_study_id>094-8151-301</org_study_id>
    <nct_id>NCT02654769</nct_id>
  </id_info>
  <brief_title>A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis</brief_title>
  <official_title>Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the safety and therapeutic equivalence of generic
      ingenol mebutate gel, 0.05% to Picato gel, 0.05% and to establish the superiority of the
      efficacy of these two products over the vehicle gel in the treatment of Actinic Keratosis
      (AK) on the trunk or extremities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Picato® (ingenol mebutate) gel is the first and only ingenol mebutate product approved by the
      FDA in 2012 for the topical treatment of AK(s) on the face and scalp (0.015% formulation) and
      on the trunk and extremities (0.05% formulation). A generic ingenol mebutate gel, 0.05% has
      been developed for the topical treatment of clinically typical, visible, and discrete
      non-hyperkeratotic, non-hypertrophic AK lesions of the trunk or extremities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Outcome Measure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of subjects in the PP population in each treatment group with complete clearance of AK lesions. Complete clearance was defined as having no (zero) clinically visible AK lesions in the Treatment Area at the Week 8 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">441</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Active Comparator Picato®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generic Ingenol Mebutate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic ingenol mebutate gel, 0.05% [Test]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Foam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel of the test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate (Picato®)</intervention_name>
    <description>Brand product</description>
    <arm_group_label>Active Comparator Picato®</arm_group_label>
    <other_name>Picato</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic Ingenol Mebutate</intervention_name>
    <description>Generic formulated to have the same therapeutic effect of the brand</description>
    <arm_group_label>Generic Ingenol Mebutate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Foam</intervention_name>
    <description>It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
    <arm_group_label>Vehicle Foam</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was a male or non-pregnant female 18 years of age or older

          -  Subject provided written informed consent.

          -  Subject was willing and able to apply the test article as directed, comply with study
             instructions, and commit to all follow-up visits for the duration of the study.

          -  Subject had a clinical diagnosis of AK at Baseline with at least four (4), but no more
             than eight (8), visible and discrete non-hyperkeratotic, non-hypertrophic AK lesions,
             each at least 4 mm in diameter, within a contiguous 25 cm2 treatment area (&quot;the
             Treatment Area&quot;) on the trunk or extremities.

          -  Subject was in good general health and free of any disease state or physical condition
             that might have impaired evaluation of AK lesions or which, in the investigator's
             opinion, exposed the subject to an unacceptable risk by study participation.

          -  Females must have been post-menopausal , surgically sterile , or have used an
             effective method of birth control , with a negative urine pregnancy test (UPT) at the
             Baseline Visit.

        Exclusion Criteria:

          -  Subject was pregnant, lactating, or was planning to become pregnant during the study.

          -  Subject was currently enrolled in an investigational drug or device study.

          -  Subject used an investigational drug or investigational device treatment within 30
             days prior to the Baseline Visit.

          -  Subject had hyperkeratotic, hypertrophic, or large mat-like AKs (e.g., AK &gt;1 cm2 in
             size) within the contiguous 25 cm2 Treatment Area.

          -  Subject had more than eight (8) AKs, independent of size, within the contiguous 25 cm2
             Treatment Area.

          -  Subject had the need or planned to be exposed to artificial tanning devices or
             excessive sunlight during the trial.

          -  Subject was immunosuppressed (e.g., HIV, systemic malignancy, graft host disease,
             etc.)

          -  Subject had experienced an unsuccessful outcome from previous ingenol mebutate therapy
             (an unsuccessful outcome was defined as after a reasonable therapeutic trial with no
             compliance issues and the topical drug did not work).

          -  Subject had a history of sensitivity to any of the ingredients in the test articles
             (see Section 9.4.2).

          -  Subject used topical creams, lotions, or gels of any kind within the selected
             Treatment Area within one (1) day prior to entry into the study.

          -  Subject used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic
             acid, lactic acid etc. &gt;5%), beta hydroxy acid (salicylic acid &gt;2%), urea &gt;5%,
             5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids
             (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area (trunk or
             extremities) within one (1) month prior to the Baseline Visit.

          -  Subject had cryodestruction, curettage, photodynamic therapy, surgical excision, or
             other treatments for AK within the selected Treatment Area (trunk or extremities)
             within one (1) month prior to the Baseline Visit.

          -  Subject used oral corticosteroid therapy, interferon, cytotoxic drugs,
             immunomodulators, immunosuppressive therapies, or retinoids within one (1) month prior
             to the Baseline Visit.

          -  Subject had dermatologic procedures or surgeries such as laser resurfacing, Psoralen +
             ultraviolet A (PUVA) therapy, ultraviolet B (UVB) therapy, chemical peels, or
             dermabrasion on the selected Treatment area (trunk or extremities) within six (6)
             months prior to the Baseline Visit.

          -  Subject had lesions suspicious for skin cancer (skin cancer not ruled out by biopsy)
             or untreated skin cancers within the selected Treatment Area (trunk or extremities).

          -  Subject had any skin pathology or condition that, in the investigator's opinion, could
             interfere with the evaluation of the test article or required the use of interfering
             topical, systemic, or surgical therapy.

          -  Subject had any condition which, in the investigator's opinion, would have made it
             unsafe or precluded the subject's ability to fully participate in this research study.

          -  Subject was unable to communicate or cooperate with the investigator due to language
             problems, poor mental development, impaired cerebral function, or physical
             limitations.

          -  Subject was known to be noncompliant or was unlikely to comply with the requirements
             of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in
             the opinion of the investigator.

          -  Subject had been previously enrolled in the same study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleg Khatsenko, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Actavis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SD Sports Medicine &amp; Family Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Savin Medical Group Research Center</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tory P. Sullivan, M.D., P.A.</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moore Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials, Inc.</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Clinic, LLC</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shideler Clinical Research Center</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bettencourt Skin Center</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Square Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research, 400 Bald Hill Road, Warwick, RI 02886</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Dermatology, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville, PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>April 14, 2020</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator Picato®</title>
          <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
Ingenol Mebutate (Picato®): Brand product</description>
        </group>
        <group group_id="P2">
          <title>Generic Ingenol Mebutate</title>
          <description>Generic ingenol mebutate gel, 0.05% [Test]
Generic Ingenol Mebutate: Generic formulated to have the same therapeutic effect of the brand</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Foam</title>
          <description>Vehicle gel of the test product
Vehicle Foam: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects in Modified Intent-to-Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>Active Comparator Picato®</title>
          <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
Ingenol Mebutate (Picato®): Brand product</description>
        </group>
        <group group_id="B2">
          <title>Generic Ingenol Mebutate</title>
          <description>Generic ingenol mebutate gel, 0.05% [Test]
Generic Ingenol Mebutate: Generic formulated to have the same therapeutic effect of the brand</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Foam</title>
          <description>Vehicle gel of the test product
Vehicle Foam: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="142"/>
            <count group_id="B4" value="439"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="9.49"/>
                    <measurement group_id="B2" value="66.6" spread="11.11"/>
                    <measurement group_id="B3" value="66.2" spread="9.07"/>
                    <measurement group_id="B4" value="66.7" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="399"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type I</title>
          <description>Typical features: Pale white skin, blue/hazel eyes, blond/red hair. Tanning ability: Always burns, does not tan.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type II</title>
          <description>Typical features: fair skin, blue eyes. Tanning ability: burns easily, tans poorly.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type III</title>
          <description>Typical features: darker white skin. Tanning ability: tans after initial burn.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type IV</title>
          <description>Typical features: light brown skin. Tanning ability: burns minimally, tans easily.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type V</title>
          <description>Typical features: brown skin. Tanning ability: rarely burns, tans darkly easily.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Outcome Measure</title>
        <description>Percentage of subjects in the PP population in each treatment group with complete clearance of AK lesions. Complete clearance was defined as having no (zero) clinically visible AK lesions in the Treatment Area at the Week 8 visit.</description>
        <time_frame>8 weeks</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator Picato®</title>
            <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
Ingenol Mebutate (Picato®): Brand product</description>
          </group>
          <group group_id="O2">
            <title>Generic Ingenol Mebutate</title>
            <description>Generic ingenol mebutate gel, 0.05% [Test]
Generic Ingenol Mebutate: Generic formulated to have the same therapeutic effect of the brand</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Foam</title>
            <description>Vehicle gel of the test product
Vehicle Foam: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Outcome Measure</title>
          <description>Percentage of subjects in the PP population in each treatment group with complete clearance of AK lesions. Complete clearance was defined as having no (zero) clinically visible AK lesions in the Treatment Area at the Week 8 visit.</description>
          <population>Per-Protocol Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Difference (Generic- Picato)</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>90% Wald's confidence interval</param_type>
            <param_value>-1.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.37</ci_lower_limit>
            <ci_upper_limit>8.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.</title>
        <time_frame>8 weeks</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Active Comparator Picato®</title>
            <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
Ingenol Mebutate (Picato®): Brand product</description>
          </group>
          <group group_id="O2">
            <title>Generic Ingenol Mebutate</title>
            <description>Generic ingenol mebutate gel, 0.05% [Test]
Generic Ingenol Mebutate: Generic formulated to have the same therapeutic effect of the brand</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Foam</title>
            <description>Vehicle gel of the test product
Vehicle Foam: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects in the PP Population in Each Treatment Group With Partial Clearance (as Having at Least 75% Reduction in the Number of Clinically Visible AK Lesions) in theTreatment Area at the Week 8 Visit.</title>
          <population>Per-Protocol Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Partial Clearance at Week 8</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Difference (Generic - Picato)</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>90% Wald's confidence interval</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.14</ci_lower_limit>
            <ci_upper_limit>7.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of the study until Week 8 (end of study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Generic Ingenol Mebutate</title>
          <description>Generic ingenol mebutate gel, 0.05% [Test]
Generic Ingenol Mebutate: Generic formulated to have the same therapeutic effect of the brand</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator Picato®</title>
          <description>Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
Ingenol Mebutate (Picato®): Brand product</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Foam</title>
          <description>Vehicle gel of the test product
Vehicle Foam: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Gastrointestinal wall thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erosion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Application site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Staphyloccocall skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Photodermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Spider vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical R&amp;D</name_or_title>
      <organization>Teva Pharmaceuticals Inc., USA</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedinfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

